Crestline Management, LP

Q2 2017 13F Combination Report, Stock Holdings

Signature - Title
John S. Cochran - Vice President
Location
Fort Worth
Holdings as of
June 30, 2017
Value $
$746M
Num holdings
128
Date filed
8/14/2017, 01:46 PM
Description
A portion of the US holdings for this investor are reported in this report and a portion are reported by other reporting manager(s).
Previous filing
Q1 2017 - May 12, 2017
Options Holdings
Showing stock holdings, see here for options holdings
Sym Weight Trade Impact Company Class Shares Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2017 Q2 compared to 2017 Q1 by default.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
John S. Cochran Vice President Fort Worth, Texas 8/14/2017

The number of shares in Juno Therapeutics Inc. reflected herein includes 17,348,799 shares held by J.T. Line Partners, L.P., over which Bratton Capital Management, L.P. and Bratton Capital, Inc. have investment discretion. Douglas K. Bratton has ultimate investment discretion over Bratton Capital Management, L.P., Bratton Capital, Inc. and Crestline Management, L.P.

List of Other Managers Reporting for Crestline Management, LP:

Name Holdings Value Location File Number
Oribel Capital Management, LP $738M New York, NY 028-17769